Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

  |  

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Sun Pharmaceutical Industries Ltd. News release: Sun Pharma announces positive results of two pivotal phase 3 clinical trials of tildrakizumab in patients with moderate to severe plaque psoriasis. 2016 May 4.
  2. AbbVie Inc. News release: AbbVie’s HUMIRA (adalimumab) receives U.S. Food and Drug Administration approval to treat adults with non-infectious intermediate, posterior and panuveitis. 2016 Jun 30.

Related Articles
    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…